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methyl)ceph-3-em-4-carboxylate is a 3rd-
generation cephalosporin developed in
198012. Like the other Ä-lactam antibiotics,
this cephalosporin inhibits peptidoglycan
synthesis and produces bacterial lysis12.
Ceftazidime is a cephalosporin active
against Escherichia coli, Citrobacter diversus,
C. freundii, Enterobacter aerogenes, E. agglo-
merans, Klebsiella spp. including K. pneu-
moniae, Proteus spp., Serratia marcescens,
Salmonella spp., Shigella spp. and Pseudo-
monas aeruginosa6. In general, the minimal
inhibitory concentration (MIC) value for
the mentioned microorganisms is
¡4 µg/m 1 2 , 2 2 . The MIC9 0 values of
ceftazidime determined for E. coli, Salmo-
nella spp., Pasteurella multocida and P.
haemolytica isolates ranged from less than
0.01 to 0.1 µg/m 21.
Studies carried out using Ä-lactams in
animals support the concept that the time
during which the free drug concentration
exceeds the MIC (T > MIC) must be
40–60 % of the inter-dose interval in order
to assure the success of the therapeutic
efficacy of the cephalosporins23,24. T >
MIC is mainly determined by the termi-
nal half-life, which is itself a hybrid pro-
cess involving plasma clearance and drug
distribution. In brief, it is suggested that
maintaining the concentration of Ä-lac-
tam antibiotics above the MICs for infect-
ing organisms is beneficial for the
treatment of Gram-negative and -positive
bacterial infections.
Ceftazidime was used to treat dairy
cows with clinical signs of inflammation
in 1 mammary gland quarter and presence
of 1 or more pathogenic microorganisms
in that quarter (3 intramammary doses of
200 mg/quarter/12 h)17. Thirty dairy cows
in full milk production were studied;
10 cows were healthy and microbio-
logically negative and the other 20 cows
had mastitis. The 10 healthy cows were
administered cefotaxime (5) and cefta-
zidime (5) via the intra-mammary route
(3 doses of 200 mg each at 12 h intervals).
Similarly, in the group of mastitic animals,
10 cows were administered ceftazidime
and the other 10 received cefotaxime. The
values for ceftazidime concentrations in
milk over time at 1 h and 12 h post-admin-
istration of the 1st dose of antibiotics in
healthy and mastitic cows were high
(1028.2 ± 723.1 and 30.5 ± 25.7 and
966.8 ± 278.0 and 131.3 ± 34.9 µg/m ,
respectively). The authors observed that
ceftazidime administered by intra-
mammary infusion to healthy and
mastitic cows was distributed from
treated to untreated quarters and the t1/2
and rate constant in milk were similar17.
The drug had good distribution from
treated to untreated quarters and the
presence of residues was observed, so
that milk destined for human consump-
tion had to be discarded for at least 72 h17.
It has been observed that low protein
binding resulted in ceftazidime penetra-
tion into the mammary gland. Binding
sites vary according to the animal species,
ranging from 20 to 30 % in mice and rats12,
10 % in humans3 and 17 % in rabbits1.
On the other hand, serum bactericidal
activity of the drug was found to be more
closely related to unbound rather than
total antibiotic concentrations and that
only the unbound drug was microbio-
logically active9. Subcutaneous or intra-
muscular (im) administration of cefta-
zidime to dogs (25 mg/kg body weight)
was effective against P. aeruginosa11. Doses
of 50 mg/kg body weight/12 h have been
recommended for the treatment of bacte-
rial infections in rabbits.
There is practically no information on
the pharmacokinetics of ceftazidime
administered parenterally to goats.
The aim of this study was to determine
the pharmacokinetic profile of cefta-
zidime administered intravenously (iv)




Lactating (LTG, n = 6) and non-lactating
(NLTG, n = 6) Creole goats with a body
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ABSTRACT
The aim of this work was to determine the pharmacokinetics of intravenous (iv) and
intramuscular (im) ceftazidime administered to lactating (LTG; n = 6) and non-lactating
(NLTG; n = 6) healthy Creole goats in 2 trials (T1 and T2). During T1 and T2, goats randomly
received a single dose of im or iv ceftazidime (10 mg/kg). Serum concentration of iv
ceftazidime in NLTG and LTG goats is best described by 2 and 3 compartment models,
respectively. The pharmacokinetic parameters of iv and im ceftazidime administered to
LTG and NLTG showed statistically significant differences (P < 0.05) in the constants (äz, T1
vs T2 [iv] 0.5 ± 0.1 vs 0.3 ± 0.1 /h; T1 vs T2 [im] 0.5 ± 0.2 vs 0.3 ± 0.1 /h) and in the mean times
(t1/2, T 1 vs T 2 [iv] 1.6 ± 0.3 vs 2.3 ± 0.6 h; T 1 vs T 2 [im] 1.6 ± 0.7 vs 2.6 ± 0.9 h) of elimination.
The bioavailability of ceftazidime in LTG and NLTG was 113.0 ± 17.8 and 96.0 ± 18.0 %,
respectively. Ceftazidime concentration in milk at 2 h was: iv = 1.9 ± 0.2 and im = 2.4 ±
0.5 µg/m ; the penetration in milk was iv = 18.3 ± 13.5 and im = 14.3 ± 10.6 %. Ninety-six
hours after iv and im administration, residues of the drug were not found in milk. In conclu-
sion, ceftazidime, when administered to goats, showed high concentration times in serum,
good penetration into milk and a bioavailability that makes it suitable to be used by the im
route.
Keywords: ceftazidime, goat, milk, pharmacokinetics.
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weight ranging from 35 to 45 kg were
used. A crossover design (2 × 2) was used
in 2 trials (T1 and T2).
The animals were maintained and
handled in accordance with the NIH
guide for the care and use of of laboratory
animals4. The research protocol was
approved by the Commission of Scientific
Research of Buenos Aires Province,
Argentina (CIC-PBA).
Trial 1
Clinically healthy animals in their 1st to
3rd lactations, weighing 30–45 kg (range),
in milk production (range 500 to 750 m /
day) and milked every 12 h, received a
single dose of 10 mg/kg of ceftazidime
randomly by the im or iv route at the start
of their 3rd week in lactation. Blood sam-
ples were collected from the jugular vein
into tubes without anti-coagulant at 0.08,
0.17, 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0,
8.0 and 12 h post-administration of the
antibiotic. Milk samples were collected
(approximately 0.5 m each) starting at
0.25 h and following the blood sampling
strategy. Milk samples were collected at
24, 36, 48, 60, 72, 84, 96, 108 and 120 h post-
administration of ceftazidime to deter-
mine the presence of residues of the drug.
Two weeks later, the same animals
received ceftazidime in equal doses and
by the same routes, but the latter were
inverted, i.e. animals that had previously
received the antibiotic iv received it
im and vice versa.
Blood and milk sampling was carried
out in the same way and at the same inter-
vals after the initial administration of the
drug.
Trial 2
Clinically healthy NLTG (n = 6) received
ceftazidime randomly administered
either by iv or im routes, in equal doses
and manner as in T1. The blood sampling
was carried out in the same way and at
the same intervals as in T1.
Processing and preservation of samples
Blood samples were allowed to clot and
then centrifuged at 3000 g for 15 min in
order to separate the serum. All the
samples (serum and milk) were stored in
individual, sterile containers at –18 °C
until further analysis.
Quantification of the antibiotic
The concentrations of ceftazidime in
serum and milk were determined by
means of the microbiological assay tech-
nique, using Geobacillus stearothermophilus
ATCC 12.980 as the test organism8. Each
sample was assayed for ceftazidime by an
agar diffusion bioassay with Mueller
Hinton Agar (Lab. Britania, Argentina)
seeded with the Geobacillus stearother-
mophilus and allowed to solidify on 23 ×
28 cm glass plates. Duplicate 25-µ portions
of each sample and of the standards were
then placed in 6 mm wells cut into the
seeded agar. The ceftazidime standards
were prepared in goat sera and milk at 20,
10, 1, 0.5, 0.4, 0.3, 0.2, 0.1, 0.15, 0.125, 0.1,
0.075, 0.05 µg/m concentrations. After
incubation of the assay plates for 6 to 8 h at
64 °C, the zone of inhibition around each
well was measured and standard curves
were prepared.
Sampling before administration of the
antibiotic showed no bacterial inhibition.
The correlation coefficient for the standard
curves prepared for all the experiments
was greater than 0.98. Intra- and inter-
assay coefficients of variation were lower
than 8 %. Sensitivity and quantification
limits of the assay for serum and milk
were 0.2 and 0.125 and 0.4 and 0.3 µg/m
(range, 0.15–0.2 and 0.1–0.125) respec-
tively.
The determination of detectable residues
of the antibiotic in milk was performed by
means of a biological test (Delvotest SP M
Gist-Brocades, Food Ingredients). The
sensitivity of Delvotest SP for ceftazidime
ranges from 0.03 to 0.015 µg/m . The
Delvotest SP is a qualitative test used by
producers, veterinarians and the dairy
industry to determine the presence of
antibiotic residues in milk.
Pharmacokinetic analysis and statistics
Pharmacokinetic analyses were carried
out with WinNonlin (V.4.1 Pharsight
Corp., Cary, NC) using standard com-
partmental methods. Akaike’s informa-
tion criterion (AIC) was used to deter-
mine which compartmental model best
adapted to the data set26. The pharmaco-
kinetic parameters calculated included
hybrid constants (C1, C2, Cz, ä1, ä2 and äz)
and were used to calculate the rate con-
stants from the central to the peripheral
compartment (k12) and vice versa (k21), the
rate constants from the central to a deep
compartment (k13) and vice versa (k31) and
the rate constants of elimination (k10)5.
The maximum milk concentration (Cmax)
and the time to achieve Cmax (tmax) were
directly observed in the data obtained for
each individual animal.
The area under the curve (AUC) was
calculated by the trapezoidal method2.
The absorption (t1/2a), rapid distribution
(t1/2ä1), slower distribution (t1/2ä2) and elimi-
nation (t1/2) half-lives, the apparent volume
of the central compartment (Vc), the
volume of distribution at steady state (Vss)
and the body clearance (CL) were calcu-
lated by standard procedures5.
The percentage of bioavailability (F)
and penetration or milk passage (P) of
ceftazidime were calculated by using the
following equation14:
F or P=
(AUC im or milk)
(AUC iv or serum)
× 100 .
The incidence of the physiological state
of the animals (LTG vs NLTG) above
pharmacokinetics parameters was ana-
lysed by means of a 2-way analysis of
variance test (Statgraphic Plus 7.0). A
P value less than 0.05 was considered sig-
nificant.
The time above the minimum inhibi-
tory concentration (T > MIC) was deter-
mined by means of the following formula:










ln is the natural logarithm, Vd the
volume of distribution, t1/2 the elimination
half-life (h) and DI the dosing interval
(h)24.
RESULTS
The mean concentrations (±SD) in
serum and milk (LTG) and in serum
(NLTG) of ceftazidime administered iv
and im are shown in Fig. 1A,B,C.
The means of the pharmacokinetic
parameters (±SD) are given in Table 1.
The pharmacokinetic parameters in serum
show statistically significant differences
(P < 0.05) between the constants of
elimination (T1(iv) 0.5 ± 0.1 vs T2 (iv)
0.3 ± 0.1, T1 (im) 0.5 ± 0.2 vs T2 (im) 0.3 ±
0.1/h) and the mean times of elimination
(T1 (iv) 1.3 ± 0.8 vs T2 (iv) 2.3 ± 0.6 and
T1 (im) 1.6 ± 0.7 vs T2 (im) 2.6 ± 0.9 h.
DISCUSSION
High concentrations in serum and milk
of ceftazidime (10 mg/kg body weight)
administered iv and im to LTG and NLTG
were found 12 h after the administration
of the antibiotic. These concentrations
exceeded the MIC for sensitive organ-
isms13,21. The high concentrations of
ceftazidime in milk agree with those
obtained in lactating cows16. The pharma-
cokinetic profile in NLTG was described
by means of an open 2-compartment
model, as previously described in hu-
mans7,19, calves21, sheep15, non-lactating
cows16 and rabbits1. In LTG as well as in
lactating cows an open 3-compartment
model was used16. Following the AIC,
it was possible to determine that the
tricompartmental model is the most
appropriate to adjust the data of the con-
centration time in serum of ceftazidime
administered by the iv route to LTG. It
differs in the slopes (phases) required to
obtain an adequate description of the
curve in results coming from NLTG,
where the model of choice was bi-
compartmental. This difference within
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the same animal species could be the
result of the different state of production
of the mammary glands of the animals in-
cluded in this study.
A single-compartment model was used
in order to describe the pharmacokinetic
behaviour of ceftazidime administered im.
In the description of the concentration
time of ceftazidime administered via the
iv route to NLTG and LTG, provided by
using models of 2 and 3 compartments, a
rapid distribution phase was observed
(t1/2ä1 = 0.2 ± 0.3 and 0.1 ± 0.03 h, respec-
tively) followed by a slower distribution
phase (t1 / 2 ä 2 = 1.6 ± 0.6 h) in the
tricompartmental model used in LTG. A
much slower phase of distribution to
deeper tissues was observed in lactating
cows (28.1 ± 19.2 h) than the phase found
in goats in this study16. This could be
attributed to the distinctive physiological
and productive conditions of the animal
species in this study. In studies in rabbits1,
sheep15 and humans20 the mean times of
rapid distribution were higher (0.258 ±
0.054, 0.22 ± 0.09 and 0.62 ± 0.01 h,
respectively) than those observed in this
study.
The half-life in serum of ceftazidime
administered iv to NLTG (2.3 ± 0.6) was
higher than those found in cows (1.4 ±
0.3 h)16, dogs (0.82 h) and rats (0.23 h)10,
humans (1.8 ± 0.2 h)25, and sheep (1.6 ±
0.2 h)15, and similar to those obtained in
rabbits (2.22 ± 0.351 h)1 and calves
(2.31 h)21. The half-life in LTG (1.6 ± 0.3 h)
was higher than that obtained in lactating
cows (1.1 ± 0.2 h)16. The faster elimination
rate constant after iv administration of
ceftazidime to LTG (0.5 ± 0.1/h) compared
with that obtained in NLTG (0.3 ± 0.1/h)
with higher mean elimination times,
agrees with a higher clearance in LTG
(103.4 ± 35.8 m /kg) vs NLTG (68.1 ±
35.8 m /kg) (not statistically demonstrated).
The volume of distribution at steady
state was not much different in quantity
between LTG (200.5 ± 79.4) and NLTG
(238.1 ± 60.3 m /kg) and also compared
with the one obtained in dogs (218 ±
7 m /kg)10, although it was lower than
those observed in cows (lactating =
489.8 ± 136.9 and non-lactating = 390.2 ±
212.9 m /kg)1 6, non-lactating sheep
(356.1 ± 208.0 m /kg)15 and non-lactating
calves (294.0 m /kg)21. These volumes of
distribution at steady state were among
the values observed for drugs with little
distribution into the extravascular tissues6.
When comparing LTG with NLTG, the
volume of distribution is not different
because the drug passes to the mammary
compartment, i.e. a a deep compartment.
However, not all the drug that arrives in
the mammary glands is eliminated
through this route; it can start circulating
again, giving rise to a clearance in lactat-
ing animals that is not statistically different
from the non-lactating animals’ clearance
results.
Although the AUC for the iv route ap-
pears different in LTG (103.4 ± 39.0 µg/m )
and NLTG (124.2 ± 34.9 µg/m ) , this was
not supported statistically, and could be
due to the passage of the antibiotic into
milk.
When ceftazidime was administered im
to LTG and NLTG it was well absorbed
and showed a high bioavailability
(113.0 ± 17.8 and 96.0 ± 18.0 %), fast
constants of absorption (4.6 ± 3.4 and
3.4 ± 0.7/h) from the site of administration
and high Cmax (67.5 ± 14.0 and 31.9 ±
12.9 µg/m ). The mean times of elimination
of ceftazidime administered im to LTG
(1.6 ± 0.7 h) and NLTG (2.6 ± 0.9 h) were
similar to those obtained for the iv route
in the same animals. Similarities were
found in the mean times of elimination of
ceftazidime administered iv (2.3 ± 0.39 h)
and im (2.1 ± 0.17 h) to calves21, suggest-
ing that the absorption does not interfere
with the terminal half-life.
Ceftazidime is a weak organic acid and
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Fig.1: A, Concentration-time in serum of ceftazidime administered by intravenous (iv) route
in lactating and non-lactating goats. B, Concentration-time in serum of ceftazidime admin-
istered by intramuscular (im) route in lactating and non-lactating goats. C, Concentra-
tion-time in milk of ceftazidime administered by intravenous (iv) and intramuscular (im)
routes in lactating goats.
its liposoluble form (non-ionised) that
allows it to pass from plasma to milk and
vice versa depends on the pKa (dissocia-
tion constant of the drug), the pH of the
environment and the drug’s ability to
bind to serum or plasma proteins. Although
ceftazidime is eliminated mainly by the
kidney and to a much lesser extent by
extrarenal mechanisms20, marked pene-
tration of the antibiotic into milk was
observed (penetration (iv) 18.3 ± 13.5
and (im) 14.3 ± 10.6 %). Those values
were lower than those observed in
bovines (penetration (iv) 47.7 ± 38.2
and (im) 51.1 ± 39.0 %)19. This lower pene-
tration can be attributed to the low milk
production of goats during Trial 1. In
another study, when cephalothin was
administered to goats, a correlation was
found between the areas under the curve,
the maximum concentrations and the
time to reach them in milk, and the volume
of milk produced by the animals18.
When ceftazidime was administered via
the iv and im route (10 mg/kg body
weight) to LTG and NLTG, the interdose
intervals necessary to obtain a T > MIC
value between 40 and 60 % for microor-
ganisms with MIC = 4 µg/m were 8 to
12 hours. However, in order to confirm
the doses and intervals, it is necessary to
have specific information about clinical
treatments in goats.
Ninety-six hours after administration of
ceftazidime iv and im, residues of the
drug determined by a standard method
used by the dairy industry were not
found in milk.
CONCLUSION
In conclusion, the high concentration
time values and the pharmacokinetic
profile of ceftazidime observed in serum
and milk makes it a promising agent for
the empirical treatment of infections in
lactating and non-lactating goats.
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